據國際文傳電訊社：俄羅斯副外長里亞布科夫表示，現在評估在阿布扎比進行的談判還爲時過早。

Betta Pharmaceuticals said its pan‑RAS inhibitor BPI‑572270 capsule completed first‑participant dosing in an Australia Phase I/II study today. Preclinical data show strong inhibition in tumor cells and xenograft models with diverse RAS mutations (KRAS, NRAS, HRAS, including G12X, G13X, Q61X) across pancreatic, non‑small‑cell lung and colorectal cancers, and report favorable pharmacokinetics and safety.

CNN reports U.S. Democratic lawmakers asked the Department of the Interior to preserve records related to construction projects.